April 2, 2009 2:41:18 pm
Scientists at the University of Cambridge have shown that screening for prostate cancer using prostate specific antigen (PSA) would lead to a reduction in advanced stage prostate cancer by up to 54 per cent.
However,there would be likely over-diagnosed cases of prostate cancer according to a study published in the British Journal of Cancer.
The researchers studied 43,842 healthy men given PSA testing as part of the Protect study to calculate the number of advanced stage prostate cancers picked up as a result of the testing.
They also worked out the length of time during which prostate tumours do not produce symptoms but are detectable by a screening test – the mean sojourn time (MST).
Best of Express Premium
The MST test is a method of calculating ‘overdiagnosis’ and was used to estimate the probability of a diagnosis which would not have caused symptoms during the patients lifetime if screening had not taken place.
In the study,1,544 men aged 50-69 were diagnosed with prostate cancer through the PSA testing. Overdiagnosis was estimated at one in 10 in the 50-59 age group and increased to three in 10,(31 per cent) in the 60-69 age group.
Study author,Dr Nora Pashayan,a Cancer Research UK scientist at the University of Cambridge said: “Our results indicate a benefit of screening to reduce the risk of advanced stage prostate cancer.
However,this is limited by overdiagnosis. Any screening strategy should take account of the potential benefits and harms of screening. A valuable target for future research would be to estimate the benefit of screening at different ages.”
Prostate cancer can be slow-growing or aggressive. Men with a non aggressive form may not develop symptoms for many years and not always need treatment the side effects of treatment can be significant.
But the difficulty is that on diagnosis,doctors can not always tell which forms of prostate cancer are aggressive and which are slow growing.
Lead author Professor David Neal,based at Cancer Research UK’s Cambridge Research Institute,said: “Overdiagnosis is a real concern. There is currently no way to tell whether a prostate cancer is aggressive,or passive. Until a test has been developed to distinguish between these,we would prefer to avoid treating patients who don’t need treatment which can lead to unnecessary side effects like impotence and incontinence. It is important that men in their 50s and 60s feel able to talk to their doctors and request a PSA test if necessary.”
📣 The above article is for information purposes only and is not intended to be a substitute for professional medical advice. Always seek the guidance of your doctor or other qualified health professional for any questions you may have regarding your health or a medical condition.
- The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.